🔎 Trials Near Me

Beranda › Glioma Pontin Intrinsik Difus › Massachusetts

Uji klinis Glioma Pontin Intrinsik Difus di Massachusetts

9 studi untuk Glioma Pontin Intrinsik Difus mencari peserta di lokasi di Massachusetts.

Kota di Massachusetts

Teks studi resmi (Bahasa Inggris)

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04870944

Targeted Pediatric High-Grade Glioma Therapy

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Susan Chi, Boston
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase awal 1Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899

Combination Therapy for the Treatment of Diffuse Midline Gliomas

  • Dana-Farber Cancer Institute Harvard University, Boston
Menerima pesertaFase 2
Usia 2 hingga 39 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT05009992

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase awal 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT04655404

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

  • Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
Menerima pesertaFase 1
12 Months – 18 Years · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT04943848

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.